CORCEPT THERAPEUTICS INC 8-K

What Happened
Corcept Therapeutics Incorporated announced on June 17, 2026 (filed as an Item 8.01 8-K) that it has resubmitted its New Drug Application (NDA) to the U.S. Food and Drug Administration for relacorilant as a treatment for patients with Cushing’s syndrome. The company issued a press release describing the resubmission (attached as Exhibit 99.1).

Key Details

• Filing date: June 17, 2026 (8-K Item 8.01 disclosure).
• Drug: relacorilant, proposed treatment for Cushing’s syndrome.
• Action: NDA resubmission to the U.S. FDA.
• Press release attached to the filing as Exhibit 99.1.

Why It Matters
This filing notifies investors that Corcept has advanced relacorilant through the regulatory process by resubmitting its NDA to the FDA—an important procedural step toward potential approval and commercialization. Investors should watch for subsequent FDA communications (e.g., filing acceptance, review timelines, or approval decisions) and company updates that could materially affect the outlook for relacorilant and Corcept’s future revenue prospects.